... to get this drug to the patients who will benefit the most," said George Yancopoulos, chief scientific officer at Tarrytown, New York-based Regeneron. The study included people who were at high risk of having heart problems since they had survived a ...
https://www.bloomberg.com/news/articles/2018-03-10/regeneron-sanofi-cut-heart-drug-s-price-as-trial-disappoints
No comments:
Post a Comment